The renewal of the marketing authorisation is the regulatory continuation of an initially time-limited approval for placing a product on the market following re-evaluation of its benefit–risk balance. Standard marketing authorisations are valid for five years initially. After the first renewal, the authorisation is valid indefinitely in principle, unless the competent authority requires a further time-limited renewal for pharmacovigilance reasons.
Re-evaluation after the initial period of validity
The initial marketing authorisation is not a definitive licence for the entire marketing period. Before it expires, the marketing authorisation holder must apply for renewal and submit a consolidated version of the dossier on quality, safety and efficacy. This takes into account all changes introduced since the granting of the authorisation. The authority evaluates whether the benefit–risk balance remains favourable and the authorisation can therefore be continued.
For centrally authorised medicinal products, Article 14 of Regulation (EC) No 726/2004 describes the five-year period of validity and the renewal. Directive 2001/83/EC contains corresponding principles for national authorisations. Practical preparation requires reliable compilation of variations, pharmacovigilance data, quality information and product information. A marketing authorisation that has been amended during its period of validity is not renewed on the basis of a historical initial dossier, but on the basis of its current regulatory status.
After a successful first renewal, the authorisation is generally valid indefinitely. However, the authority may order a further five-year renewal for justified pharmacovigilance reasons, for example if patient exposure is still insufficient. Renewal is therefore a risk-based regulatory checkpoint and not merely an administrative date.
Distinction from annual re-assessment and variation notification
Renewal is to be distinguished from the annual re-assessment of a marketing authorisation under exceptional circumstances. In that case, the specific obligations and their impact on the benefit–risk balance are reviewed every year, because comprehensive data cannot in principle be provided in full. By contrast, the renewal of a standard marketing authorisation reviews the authorisation after its initial period of validity; it is not equivalent to annual monitoring of conditions.
Likewise, a renewal is not a variation to the marketing authorisation. A variation applies for a specific change to the authorised conditions, for example an adaptation of quality, safety, efficacy or product information. Renewal evaluates the continuing authorisation status as a whole. Changes during the period of validity belong in the consolidated dossier version, but do not replace the renewal procedure.
Distinction from the sunset clause
Renewal answers the question whether a valid, time-limited marketing authorisation should continue after re-evaluation of the benefit–risk balance. The sunset clause, by contrast, concerns the lapse of a marketing authorisation due to lack of actual market presence. A marketing authorisation may lose its validity under the sunset rule if the medicinal product is not placed on the market within three years or is no longer on the market for three consecutive years.
Both provisions may be relevant in the lifecycle of the same product, but are based on different grounds. Renewal is linked to duration and current evidence; the sunset clause to actual placing on the market. The sunset clause is neither a negative benefit–risk decision nor a failure to renew. For portfolio and supply planning, both review pathways should be monitored separately.
The distinction is particularly important when a product is not marketed during the initial authorisation period or must be temporarily withdrawn from the market. Even a technically well-prepared renewal dossier does not then answer the question whether the conditions of the sunset clause are met. Conversely, documented market presence does not replace the renewed regulatory benefit–risk evaluation for renewal.
Both reviews should therefore be managed in a clear regulatory calendar with separate responsibilities.
Relevance for clinical trials
For clinical teams, renewal is relevant because study and safety data continue to support the ongoing benefit–risk evaluation even after initial authorisation. Post-authorisation studies, new findings on risks, exposure data and changes in therapeutic practice must be integrated into a consolidated regulatory presentation. Incomplete data handovers between clinical development, pharmacovigilance and regulatory affairs can complicate the preparation of renewal. An early-maintained data inventory facilitates traceability of the product history.
Full-service CROs such as Mediconomics support the integration of clinical data, pharmacovigilance, medical writing, data management and regulatory project management. They can prepare updated safety and efficacy evaluations for the renewal dossier, consolidate the documentation of previous changes, and align work plans for required post-authorisation studies with regulatory timelines.
Frequently Asked Questions (FAQ)
How long is a standard marketing authorisation initially valid?
It is initially valid for five years and is re-evaluated for benefit–risk balance upon application before expiry.
Is the marketing authorisation always valid indefinitely after the first renewal?
In principle, yes. However, the competent authority may require a further five-year renewal for justified pharmacovigilance reasons.
Does the sunset clause renew a marketing authorisation?
No. On the contrary, it governs the lapse of a marketing authorisation in the event of failure to place it on the market over the legally specified period.
Regulatory References
- Regulation (EC) No 726/2004, Article 14 — governs duration, renewal and possible further time-limitation of central marketing authorisations.
- Directive 2001/83/EC, Article 24 — contains the corresponding provision for national authorisations.
- EMA, Renewal and annual re-assessment — explains documentation and distinction of special authorisation types.